Clinical TrialsThe 52-week extension results for the ENLIGHTEN-1 trial are expected to include data from a repeat treatment group, which might show a different therapeutic profile compared to the 24 weeks single implant data.
Regulatory EngagementLYRA remains confident in the non-polyp opportunity and aims to engage with the FDA in the future.
Subgroup AnalysisSubgroup analysis with nasal polyps has shown a positive effect versus sham in 3CS and nasal congestion scores, highlighting potential areas for successful treatment outcomes.